Viking Therapeutics price target raised to $120 from $38 at Truist

Truist analyst Joon Lee raised the firm’s price target on Viking Therapeutics to $120 from $38 and keeps a Buy rating on the shares after the firm raised VK2735 estimates after seeing further evidence of “what appears to be best-in-class GLP1 profile.” VK2735 appears to be about twice as effective in weight loss compared to tirzepatide and numerically superior to even triple agonist retatrutide, all while exhibiting superior tolerability, the analyst tells investors. All-in, the firm models non-risk adjusted VK2735 U.S. peak sales of $35B in 2043 for obesity plus diabetes.